Endogenous interleukin-12 only plays a key pathogenetic role in non- obese diabetic mouse diabetes during the very early stages of the disease

Immunology

Volumn 97, Issue 3, 1999, Pages 367-370

  Nicoletti, F ^a,d   Di Marco, R ^b   Zaccone, P ^b   Magro, G ^b   Di Mauro, M ^b   Grasso, S ^b   Meroni, P L ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c IRCCS   (Italy)

^d NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIABETES MELLITUS; DIABETOGENESIS; DISEASE COURSE; FEMALE; GENE EXPRESSION; INSULITIS; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; INTERLEUKIN-12; MICE; MICE, INBRED NOD; RATS;

EID: 0033048575     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00836.x     Document Type: Article

References (27)

1. 1. BACH J.F. (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15, 516.
2. 2. RABINOVITCH A. (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 43, 613.
3. 3. MANDRUP-POULSEN T., NERUP J., REIMERS J.J. et al. (1996) Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Eur J Endocrinol 134, 21.
4. 4. RABINOVITCH A. (1998) An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabets Metab Rev 14, 129.
5. 5. ROTHE H. & KOLB H. (1998) The APC1 concept of type 1 diabetes. Autoimmunity 27, 179.
6. 6. RABINOVITCH A., SUAREZ P.W. & SORENSEN O. (1996) Interleukin-12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun 9, 645.
7. 7. ROTHE H., BURKARI V., FAUST A. & KOLB H. (1996) Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabetologia 39, 119.
8. 8. ZIPRIS D., GREINER D.L., MALKANI S., WHALEN B., MORDES J.P. & ROSSINI A.A. (1996) Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic rats. J Immunol 156, 1315.
9. 9. TREMBLEAU S., PENNA G., BOSI E., MORTARA A., GATELY M.K. & ADORINI L., (1995) Interleukin. 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181, 817.
10. 2. Diabetologia 39, 119.
11. 11. YASUDA H., NAGATA M., ARISAWA K. et al. (1998) Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 102, 1807.
12. 12. SZELACHOWSKA M., KRETOWSKI A. & KINALSKA I. (1997) Increased in vitro interleukin-12 production from by peripheral blood in high-risk IDDM first degree relatives. Horm Metab Res 29, 168.
13. 13. STERNESJO J. & SANDLER S. (1998) Effects of interleukin-12 in vitro on pancreatic islets isolated from normal rodents and from non-obese diabetic mice. J Endocrinol 158, 69.
14. 14. O'HARA R.J., HENDERSON S.L. & NAGELIN A. (1996) Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann N Y Acad Sci 759, 241.
15. 15. TREMBLEAU S., PENNA G., GREGORI S., GATELY M.C. & ADORINI L. (1997) Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 27, 2330.
16. 16. NEURATH M.F., FUSS I., KELSALL B.L., STUBER E. & STROBER W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182, 1281.
17. 17. CONSTANTINESCU C.S., WYSOCKA M., HILLIARD B. et al. (1998) Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 161, 5097.
18. 18. NICOLETTI F., ZACCONE P., DI MARCO R. et al. (1996) The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in NOD mouse. Endocrinology 137, 5567.
19. 19. PARISH N.M., HUTCHINGS P.R., O'REILLY L. et al. (1995) Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Immunol Rev 144, 269.
20. 20. KURASAWA K., SAKAMOTO A., MAEDA T. et al. (1993) Short-term administration of anti-L3T4 MoAb prevents diabetes in NOD mice. Clin Exp Immunol 91, 376.
21. 21. NICOLETTI F., DI MARCO R., BARCELLINI W. et al. (1994) Protection from experimental autoimmune diabetes in the nonobese diabetic mouse by soluble interleukin-1 receptor. Eur J Immunol 24, 1843.
22. 22. CAILLEAU C., DIU-HERCEND A., RUUTH E., WESTWOOD R. & CARNAUD C. (1997) Treatment with neutralizing antibodies specific for IL-1 beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46, 937.
23. 23. PENNLINE K.J., ROQUE-GAFFNEY E. & MONAHAM R. (1994) Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 71, 169.
24. 24. CAMPBELL I.L., KAY T.W.H. & OXBROW & HARRISON L.C. (1991) Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Whei mice. J Clin Invest 87, (739).
25. 25. DEBRAY-SACHS M., CARNAUD C., BOITARD C. et al. (1991) Prevention of diabetes in NOD mice treated with antibody to murine IFN-Γ. J Autoimmun 4, 237.
26. 26. CAMERON M.J., ARREAZA G.A., ZUCKER P. et al. (1997) IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 159, 4686.
27. 27. ROTHE H., JENKINS N.A., COPEAND N.G. & KOLB H. (1997) Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF which is located near Idd2. J Clin Invest 99, 469.